Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CSNK2A1 | P68400 | 4/20 | 0.46 |
| ▸ | CDK7 | P50613 | 8/20 | 0.43 |
| ▸ | CCNH | P51946 | 8/20 | 0.43 |
| ▸ | MNAT1 | P51948 | 8/20 | 0.43 |
| ▸ | MAPK3 | P27361 | 3/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.40 |
| ▸ | CDK5R1 | Q15078 | 1/20 | 0.40 |
| ▸ | JAK3 | P52333 | 1/20 | 0.35 |
| ▸ | TTK | P33981 | 3/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.34 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.34 |
| ▸ | CCNK | O75909 | 1/20 | 0.34 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.34 |
| ▸ | CDK2 | P24941 | 1/20 | 0.34 |
| ▸ | CDK9 | P50750 | 1/20 | 0.34 |
| ▸ | CDK13 | Q14004 | 1/20 | 0.34 |
| ▸ | CDK12 | Q9NYV4 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18122195 | 1.00 | CSNK2A1 (0.46) | CSNK2A1CDK7CCNHMNAT1MAPK3 | |
| SCHEMBL21473010 | 0.90 | CSNK2A1 (0.52) | CSNK2A1CDK7CCNHMNAT1CDK5 | |
| SCHEMBL25737109 | 0.89 | CSNK2A1 (0.47) | CSNK2A1CDK7CCNHMNAT1CDK5 | |
| SCHEMBL25736235 | 0.89 | CSNK2A1 (0.45) | CSNK2A1CDK7CCNHMNAT1MAPK3 | |
| SCHEMBL18122196 | 0.85 | CSNK2A1 (0.44) | CSNK2A1JAK3TTKCYP3A4CDK9 | |
| SCHEMBL25736291 | 0.85 | CSNK2A1 (0.44) | CSNK2A1JAK3TTKCYP3A4CDK9 | |
| SCHEMBL18122197 | 0.83 | CSNK2A1 (0.46) | CSNK2A1CDK7CCNHCDK5CDK5R1 | |
| SCHEMBL20549671 | 0.83 | CSNK2A1 (0.46) | CSNK2A1CDK7CCNHCDK5CDK5R1 | |
| SCHEMBL20550117 | 0.82 | CSNK2A1 (0.46) | CSNK2A1CDK7CCNHMNAT1MAPK3 | |
| SCHEMBL20550115 | 0.82 | CSNK2A1 (0.46) | CSNK2A1CDK7CCNHMNAT1MAPK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-RE50776-E1 | Inhibitors of cyclin-dependent kinases | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2026-02-03 | — | — | US | disclosed |
| US-12098154-B2 | Inhibitors of cyclin-dependent kinases | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2024-09-24 | — | — | US | disclosed |
| US-20230183240-A9 | INHIBITORS OF CYCLIN-DEPENDENT KINASES | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2023-06-15 | — | — | US | disclosed |
| US-20230183240-A9 | INHIBITORS OF CYCLIN-DEPENDENT KINASES | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2023-06-15 | — | — | US | disclosed |
| US-20230183240-A9 | INHIBITORS OF CYCLIN-DEPENDENT KINASES | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2023-06-15 | — | — | US | disclosed |
| EP-3273966-B1 | INHIBITORS OF CYCLIN-DEPENDENT KINASES | DANA FARBER CANCER INST INC (US) | 2023-05-03 | — | — | EP | disclosed |
| EP-3273966-B1 | INHIBITORS OF CYCLIN-DEPENDENT KINASES | DANA FARBER CANCER INST INC (US) | 2023-05-03 | — | — | EP | disclosed |
| US-20230114207-A1 | THE COMBINATION OF CYCLIN DEPENDENT KINASE 7 INHIBITOR AND IMMUNOTHERAPY FOR TREATMENT OF CANCER | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2023-04-13 | — | — | US | disclosed |
| US-20220242865-A1 | INHIBITORS OF CYCLIN-DEPENDENT KINASES | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2022-08-04 | — | — | US | disclosed |
| US-11325910-B2 | Inhibitors of cyclin-dependent kinases | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2022-05-10 | — | — | US | disclosed |
| US-11325910-B2 | Inhibitors of cyclin-dependent kinases | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2022-05-10 | — | — | US | disclosed |
| CN-107427521-B | Inhibitors of cyclin dependent kinases | 达纳-法伯癌症研究所股份有限公司 | 2021-08-03 | — | — | CN | disclosed |
| WO-2021133601-A1 | THE COMBINATION OF CYCLIN DEPENDENT KINASE 7 INHIBITOR AND IMMUNOTHERAPY FOR TREATMENT OF CANCER | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2021-07-01 | — | — | WO | disclosed |
| US-20200277292-A1 | INHIBITORS OF CYCLIN-DEPENDENT KINASES | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2020-09-03 | — | — | US | disclosed |
| US-20200277292-A1 | INHIBITORS OF CYCLIN-DEPENDENT KINASES | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2020-09-03 | — | — | US | disclosed |
| US-10550121-B2 | Inhibitors of cyclin-dependent kinases | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2020-02-04 | — | — | US | disclosed |
| US-10550121-B2 | Inhibitors of cyclin-dependent kinases | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2020-02-04 | — | — | US | disclosed |
| US-20190315747-A9 | INHIBITORS OF CYCLIN-DEPENDENT KINASES | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2019-10-17 | — | — | US | disclosed |
| US-20190315747-A9 | INHIBITORS OF CYCLIN-DEPENDENT KINASES | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2019-10-17 | — | — | US | disclosed |
| US-20180319801-A1 | INHIBITORS OF CYCLIN-DEPENDENT KINASES | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2018-11-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11325910-B2 | Inhibitors of cyclin-dependent kinases | CDK3, CDK13, CDK1 | CSNK2A1 403/4885CDK7 12/4885CCNH 46/4885 |
| US-20220242865-A1 | INHIBITORS OF CYCLIN-DEPENDENT KINASES | CDK3, CDK13, CDK1 | CSNK2A1 403/4885CDK7 12/4885CCNH 46/4885 |
| US-20200277292-A1 | INHIBITORS OF CYCLIN-DEPENDENT KINASES | CDK3, CDK13, CDK1 | CSNK2A1 403/4885CDK7 12/4885CCNH 46/4885 |
| US-10550121-B2 | Inhibitors of cyclin-dependent kinases | CDK3, CDK13, CDK1 | CSNK2A1 403/4885CDK7 12/4885CCNH 46/4885 |
| US-20180319801-A1 | INHIBITORS OF CYCLIN-DEPENDENT KINASES | CDK3, CDK13, CDK1 | CSNK2A1 403/4885CDK7 12/4885CCNH 46/4885 |
| US-12098154-B2 | Inhibitors of cyclin-dependent kinases | CDK3, CDK13, CDK1 | CSNK2A1 403/4885CDK7 12/4885CCNH 46/4885 |
| US-20230114207-A1 | THE COMBINATION OF CYCLIN DEPENDENT KINASE 7 INHIBITOR AND IMMUNOTHERAPY FOR TREATMENT OF CANCER | CDK7, CDC7, CDK8 | CSNK2A1 67/4885CDK7 1/4885CCNH 45/4885 |
| US-20190315747-A9 | INHIBITORS OF CYCLIN-DEPENDENT KINASES | CDK3, CDK13, CDK1 | CSNK2A1 403/4885CDK7 12/4885CCNH 46/4885 |
| US-20230183240-A9 | INHIBITORS OF CYCLIN-DEPENDENT KINASES | CDK3, CDK13, CDK1 | CSNK2A1 403/4885CDK7 12/4885CCNH 46/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.